Cadila Pharma to set up plant in Uzbekistan

Cadila Pharma to set up plant in Uzbekistan

A representative delegation from India, led by the Chief Minister of Gujarat State, Vijaybhai Rupani participated in the I International Investment Forum “Open Andijan”. The forum signed an agreement with the Indian company Cadila Pharmaceuticals Limited on the phased implementation of integrated pharmaceutical production with foreign direct investment of $50 million in the Andijan Pharm pharmaceutical zone.

The delegation, which consists of 120 people, includes representatives of the state government and large Indian companies working in the pharmaceutical industry, the automotive, jewelry, food and textile industries, information technology, healthcare, agricultural processing and others. Among the members of the delegation are representatives of leading Indian companies such as Cadila Pharmaceuticals Limited, Reliance Industries, Minda Group, Shalby Hospital, Adani, Banas Dairy and others. Gujarat State Minister participated in the opening of the investment forum and also met with the governor of the Andijan region Sh. Abdurakhmonov.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry.

Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia.